Efficacy of HDAC Inhibitors in Driving Peroxisomal β-Oxidation and Immune Responses in Human Macrophages: Implications for Neuroinflammatory Disorders
Biomolecules · 2023
DOI: 10.3390/biom13121696 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules, 2023. Verfasst von Andrea Villoria-González und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathobiology of the Nervous System, Center for Brain Research, Medical University of Vienna, 1090 Vienna, Austria. Hauptthemen laut MEDLINE: Histone Deacetylase Inhibitors, ATP-Binding Cassette Transporters. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: FWF Austrian Science Fund, Austrian Science Fund, State Ministry of Baden-Württemberg for Economic Affairs, Labour and Tourism.
Abstract (Originalsprache)
Elevated levels of saturated very long-chain fatty acids (VLCFAs) in cell membranes and secreted lipoparticles have been associated with neurotoxicity and, therefore, require tight regulation. Excessive VLCFAs are imported into peroxisomes for degradation by β-oxidation. Impaired VLCFA catabolism due to primary or secondary peroxisomal alterations is featured in neurodegenerative and neuroinflammatory disorders such as X-linked adrenoleukodystrophy and multiple sclerosis (MS). Here, we identified that healthy human macrophages upregulate the peroxisomal genes involved in β-oxidation during myelin phagocytosis and pro-inflammatory activation, and that this response is impaired in peripheral macrophages and phagocytes in brain white matter lesions in MS patients. The pharmacological targeting of VLCFA metabolism and peroxisomes in innate immune cells could be favorable in the context of neuroinflammation and neurodegeneration. We previously identified the epigenetic histone deacetylase (HDAC) inhibitors entinostat and vorinostat to enhance VLCFA degradation and pro-regenerative macrophage polarization. However, adverse side effects currently limit their use in chronic neuroinflammation. Here, we focused on tefinostat, a monocyte/macrophage-selective HDAC inhibitor that has shown reduced toxicity in clinical trials. By using a gene expression analysis, peroxisomal β-oxidation assay, and live imaging of primary human macrophages, we assessed the efficacy of tefinostat in modulating VLCFA metabolism, phagocytosis, chemotaxis, and immune function. Our results revealed the significant stimulation of VLCFA degradation with the upregulation of genes involved in peroxisomal β-oxidation and interference with immune cell recruitment; however, tefinostat was less potent than the class I HDAC-selective inhibitor entinostat in promoting a regenerative macrophage phenotype. Further research is needed to fully explore the potential of class I HDAC inhibition and downstream targets in the context of neuroinflammation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathobiology of the Nervous System, Center for Brain Research, Medical University of Vienna, 1090 Vienna, Austria.
- Department of Neuroscience, Centre de Recherche du CHUM, Université de Montréal, Montréal, QC H2X 0A9, Canada.
- Institut du Cerveau-Paris Brain Institute-ICM, Inserm, CNRS, APHP, Hôpital Pitié Salpétrière-University Hospital, Sorbonne University, DMU Neuroscience 6, 75013 Paris, France.
- Division of Immune Receptors and T Cell Activation, Institute of Immunology Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, 1090 Vienna, Austria.
- Department of Neurology, Comprehensive Center for Clinical Neurosciences and Mental Health, Medical University of Vienna, 1090 Vienna, Austria.
- Department of Pharma and Biotech, NMI Natural and Medical Sciences Institute, University of Tübingen, 72770 Reutlingen, Germany.
ORCID-Profile: Bettina Zierfuss, Elisabeth Heuböck, Violetta Zujovic, Johannes Berger, Isabelle Weinhofer
Förderung
- FWF Austrian Science Fund
- Austrian Science Fund
- State Ministry of Baden-Württemberg for Economic Affairs, Labour and Tourism
Zitieren
APA
Villoria-González, A., Zierfuss, B., Parzer, P., Heuböck, E., Zujovic, V., Waidhofer-Söllner, P., Ponleitner, M., Rommer, P., Göpfert, J., Forss-Petter, S., Berger, J., & Weinhofer, I. (2023). Efficacy of HDAC Inhibitors in Driving Peroxisomal β-Oxidation and Immune Responses in Human Macrophages: Implications for Neuroinflammatory Disorders. Biomolecules. https://doi.org/10.3390/biom13121696
Vancouver
Villoria-González A, Zierfuss B, Parzer P, Heuböck E, Zujovic V, Waidhofer-Söllner P, et al. Efficacy of HDAC Inhibitors in Driving Peroxisomal β-Oxidation and Immune Responses in Human Macrophages: Implications for Neuroinflammatory Disorders. Biomolecules. 2023. doi:10.3390/biom13121696
BibTeX
@article{VilloriaGonzlez2023,
author = {Villoria-González, Andrea and Zierfuss, Bettina and Parzer, Patricia and Heuböck, Elisabeth and Zujovic, Violetta and Waidhofer-Söllner, Petra and Ponleitner, Markus and Rommer, Paulus and Göpfert, Jens and Forss-Petter, Sonja and Berger, Johannes and Weinhofer, Isabelle},
title = {Efficacy of HDAC Inhibitors in Driving Peroxisomal β-Oxidation and Immune Responses in Human Macrophages: Implications for Neuroinflammatory Disorders},
journal = {Biomolecules},
year = {2023},
doi = {10.3390/biom13121696}
}
EUVIMED